Literature DB >> 20083299

Androgen receptor is a potential therapeutic target for bladder cancer.

Ji-Tao Wu1, Bang-Min Han, Sheng-Qiang Yu, Hui-Ping Wang, Shu-Jie Xia.   

Abstract

OBJECTIVES: To investigate whether androgen receptor (AR) could serve as a potential molecular target for the treatment of bladder cancer.
METHODS: Cell proliferation, apoptosis, and migration capacity were determined in human transitional carcinoma cell lines T24 and 253-J treated with small interfering RNA directed against AR, and expression levels of growth- and metastasis-related genes were assessed using quantitative reverse transcriptase-polymerase chain reaction. Tumor cell growth and apoptosis were also evaluated in vivo in T24 tumor-bearing nude mice receiving electroporation-assisted administration of anti-AR small interfering RNA.
RESULTS: AR expression knockdown produced increased apoptosis, decreased proliferation, and migration of bladder cancer cells. Cyclin D1, Bcl-x(L), and matrix metallopeptidase-9 gene expression were also reduced with AR knockdown, which might have contributed to the altered biological behavior of cancer cells. In vivo experiments showed that silencing AR expression, by interference aided by electroporation, significantly suppressed AR-positive bladder tumor growth with decreased cell proliferation and increased apoptotic rates.
CONCLUSIONS: Downregulation of AR expression inhibits bladder cancer cell growth in vitro and in vivo, implying that its use might be a potential therapeutic target for the treatment of bladder cancer. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20083299     DOI: 10.1016/j.urology.2009.10.041

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  32 in total

Review 1.  The androgen receptor and stem cell pathways in prostate and bladder cancers (review).

Authors:  Katarzyna Marcinkiewicz; Kymora B Scotland; Stephen A Boorjian; Emeli M Nilsson; Jenny Liao Persson; Per Anders Abrahamsson; Cinzia Allegrucci; Ieuan A Hughes; Lorraine J Gudas; Nigel P Mongan
Journal:  Int J Oncol       Date:  2011-09-28       Impact factor: 5.650

2.  Lower risk in parous women suggests that hormonal factors are important in bladder cancer etiology.

Authors:  Carol A Davis-Dao; Katherine D Henderson; Jane Sullivan-Halley; Huiyan Ma; Dee West; Yong-Bing Xiang; Manuela Gago-Dominguez; Mariana C Stern; J Esteban Castelao; David V Conti; Malcolm C Pike; Leslie Bernstein; Victoria K Cortessis
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-04-14       Impact factor: 4.254

3.  Antitumor effects of bladder cancer-specific adenovirus carrying E1A-androgen receptor in bladder cancer.

Authors:  Z Zhai; Z Wang; S Fu; J Lu; F Wang; R Li; H Zhang; S Li; Z Hou; H Wang; R Rodriguez
Journal:  Gene Ther       Date:  2012-01-05       Impact factor: 5.250

Review 4.  Targeted therapies in bladder cancer: an overview of in vivo research.

Authors:  Kim E M van Kessel; Tahlita C M Zuiverloon; Arnout R Alberts; Joost L Boormans; Ellen C Zwarthoff
Journal:  Nat Rev Urol       Date:  2015-09-22       Impact factor: 14.432

5.  Alterations in ubiquitin ligase Siah-2 and its corepressor N-CoR after P-MAPA immunotherapy and anti-androgen therapy: new therapeutic opportunities for non-muscle invasive bladder cancer.

Authors:  Patrick Vianna Garcia; Letícia Montanholi Apolinário; Petra Karla Böckelmann; Iseu da Silva Nunes; Nelson Duran; Wagner José Fávaro
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

6.  Implication of androgen receptor in urinary bladder cancer: a critical mini review.

Authors:  Arshad H Rahmani; Mohammad Alzohairy; Ali Yousif Y Babiker; Amjad A Khan; Salah M Aly; Moshahid A Rizvi
Journal:  Int J Mol Epidemiol Genet       Date:  2013-09-12

7.  The effects of early versus delayed castration targeting androgen on prolonging survival in a mouse model of bladder cancer.

Authors:  Zaixian Zhang; Qingquan Xu; Xiaobo Huang; Jia Yang; Yanhong Xu; Guixiang Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

8.  Enzalutamide as an androgen receptor inhibitor prevents urothelial tumorigenesis.

Authors:  Takashi Kawahara; Satoshi Inoue; Eiji Kashiwagi; Jinbo Chen; Hiroki Ide; Taichi Mizushima; Yi Li; Yichun Zheng; Hiroshi Miyamoto
Journal:  Am J Cancer Res       Date:  2017-10-01       Impact factor: 6.166

9.  Compound A Inhibits Bladder Cancer Growth Predominantly via Glucocorticoid Receptor Transrepression.

Authors:  Yichun Zheng; Hitoshi Ishiguro; Hiroki Ide; Satoshi Inoue; Eiji Kashiwagi; Takashi Kawahara; Mehrsa Jalalizadeh; Leonardo O Reis; Hiroshi Miyamoto
Journal:  Mol Endocrinol       Date:  2015-08-31

10.  Protective effects of ascorbic acid against the genetic and epigenetic alterations induced by 3,5-dimethylaminophenol in AA8 cells.

Authors:  Ming-Wei Chao; Pınar Erkekoglu; Chia-Yi Tseng; Wenjie Ye; Laura J Trudel; Paul L Skipper; Steven R Tannenbaum; Gerald N Wogan
Journal:  J Appl Toxicol       Date:  2014-09-01       Impact factor: 3.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.